Will the U.S. government announce additional funding for H5N1 vaccine development by end of 2025?
Yes • 50%
No • 50%
Official announcements from the U.S. Department of Health and Human Services
U.S. Awards Moderna $590 Million for H5N1 Bird Flu Vaccine mRNA-1018
Jan 17, 2025, 09:08 PM
The U.S. Department of Health and Human Services (HHS) has awarded Moderna Inc. $590 million to advance the development of a bird flu vaccine, specifically targeting H5N1 Avian Flu. This funding, adding to the $176 million awarded last year, is part of a broader effort by the Biden-Harris Administration to address emerging disease threats, including avian influenza. The investment aims to enhance disease surveillance, strengthen laboratory testing, and ensure ongoing monitoring of the virus's impact. Moderna's mRNA-based vaccine, mRNA-1018, is set to advance into a phase 3 trial following positive results in earlier phases. The initiative reflects a commitment to accelerating the development of new vaccines to stay ahead of potential pandemics.
View original story
Yes • 50%
No • 50%
Less than $500 million • 25%
$1 billion to $1.5 billion • 25%
$500 million to $999 million • 25%
More than $1.5 billion • 25%
No significant new policy/action • 25%
Develop new antiviral treatments • 25%
Increase vaccine stockpile • 25%
Enhance surveillance measures • 25%
Vaccine A • 25%
Vaccine B • 25%
Both equally • 25%
Neither • 25%
No significant action • 25%
Public health advisory issued • 25%
Travel restrictions implemented • 25%
Widespread vaccination campaign initiated • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Less than 10 million • 25%
More than 100 million • 25%
50 to 100 million • 25%
10 to 50 million • 25%
Delayed • 25%
Successful with FDA approval recommendation • 25%
Successful without FDA approval recommendation • 25%
Unsuccessful • 25%